A Study of Alpharadin® With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)
Phase: Phase 1/Phase 2
Diagnosis: Prostate Cancer
NCT ID: NCT01106352
(View complete trial on ClinicalTrials.gov)
DFCI Protocol ID: 10-232
The main purpose of this study is to establish a recommended dose of Alpharadin® to be used in combination with docetaxel in patients with bone metastases from castration-resistant prostate cancer and to investigate safety and explore efficacy of the recommended dose.
Dana-Farber Cancer Institute, Beth-Israel Deaconess Medical Center
Dana-Farber Cancer Institute
Glenn Bubley, MD,
Beth Israel Deaconess Medical Center
Beth-Israel Deaconess Medical Center:
Cancer Trials Call Center, 617-667-3060
Dana-Farber Cancer Institute:
Judith Prisby, 617-632-5068,
Main Inclusion Criteria:
- Histologically or cytologically confirmed adenocarcinoma of the prostate.
- Two or more bone metastases (hot spots) confirmed by bone scintigraphy within 12
weeks prior to study entry
- Known castration-resistant disease
- Karnofsky Performance Status (KPS): ≥70% within 14 days before start of study
treatment (ECOG 1)
- Life expectancy at least 6 months.
- Acceptable hematology and serum biochemistry screening values
- Eligible for use of docetaxel according to the product information (package insert or
Main Exclusion Criteria:
- Has received an investigational therapeutic drug within the last 4 weeks prior to
start of study treatment, or is scheduled to receive one during the treatment period.
- Has received external radiotherapy within the last 4 weeks prior to start of study
- Has an immediate need for radiotherapy.
- Has received prior hemibody external radiotherapy .
- Has received systemic radiotherapy (e.g. samarium, strontium etc.) for the treatment
of bone metastases.
- Has received cytotoxic chemotherapy within the last 4 weeks prior to start of study
treatment, or has not recovered to grade 1 or 0 from adverse events due to cytotoxic
chemotherapy administered more than 4 weeks earlier.
- Has received more than ten previous infusions of docetaxel.
- Previous known experience of grade ≥ 3 docetaxel related toxicities or docetaxel
toxicity related dose interruption or discontinuation.
- Previous use of G-CSF for persistent neutropenia after docetaxel treatment.
- Has received blood transfusion or erythropoietin (EPO) within the last 4 weeks prior
to start of study treatment.
- Has received prior treatment with Alpharadin.
- Malignant lymphadenopathy exceeding 3 cm in short-axis diameter.
- Symptomatic nodal disease, i.e. scrotal, penile or leg edema.
- Visceral metastases from CRPC (>2 lung and/or liver metastases [size ≥2cm]), as
assessed by CT scan of the chest/abdomen/pelvis within the last 8 weeks prior to
start of study treatment.
- Uncontrolled loco-regional disease.
- Other primary tumor (other than CRPC) including haematological malignancy present
within the last 5 years (except non-melanoma skin cancer or low-grade superficial
- Has imminent or established spinal cord compression based on clinical findings and/or
- Unmanageable fecal incontinence.